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BACKGROUND: EXSCEL (Exenatide Study of Cardiovascular Event Lowering) 
assessed the impact of once-weekly exenatide 2 mg versus placebo in patients 
with type 2 diabetes mellitus, while aiming for glycemic equipoise. Consequently, 
greater drop-in of open-label glucose-lowering medications occurred in the 
placebo group. Accordingly, we explored the potential effects of their unbalanced 
use on major adverse cardiovascular events (MACE), defined as cardiovascular 
death, nonfatal myocardial infarction or nonfatal stroke, and all-cause mortality 
(ACM), given that some of these agents are cardioprotective.
METHODS: Cox hazard models were performed by randomized treatment 
for drug classes where >5% open-label drop-in glucose-lowering medication 
occurred, and for glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 3.0%) 
using three methodologies: drop-in visit right censoring, inverse probability for 
treatment weighting (IPTW), and applying drug class risk reductions.
RESULTS: Baseline glucose-lowering medications for the 14 752 EXSCEL 
participants (73.1% with previous cardiovascular disease) did not differ between 
treatment groups. During median 3.2 years follow-up, open-label drop-in 
occurred in 33.4% of participants, more frequently with placebo than exenatide 
(38.1% versus 28.8%), with metformin (6.1% versus 4.9%), sulfonylurea (8.7% 
versus 6.9%), dipeptidyl peptidase-4 inhibitors (10.6% versus 7.5%), SGLT-
2i (10.3% versus 8.1%), GLP-1 RA (3.4% versus 2.4%), and insulin (13.8% 
versus 9.4%). The MACE effect size was not altered meaningfully by right 
censoring, but the favorable HR for exenatide became nominally significant in 
the sulfonylurea and any glucose-lowering medication groups, while the ACM 
HR and p-values were essentially unchanged. IPTW decreased the MACE HR from 
0.91 (P=0.061) to 0.85 (P=0.008) and the ACM HR from 0.86 (P=0.016) to 0.81 
(P=0.012). Application of literature-derived risk reductions showed no meaningful 
changes in MACE or ACM HRs or P values, although simulations of substantially 
greater use of drop-in cardioprotective glucose-lowering agents demonstrated 
blunting of signal detection.
CONCLUSIONS: EXSCEL-observed HRs for MACE and ACM remained robust 
after right censoring or application of literature-derived risk reductions, but 
the exenatide versus placebo MACE effect size and statistical significance were 
increased by IPTW. Effects of open-label drop-in cardioprotective medications 
need to be considered carefully when designing, conducting, and analyzing 
cardiovascular outcome trials of glucose-lowering agents under the premise of 
glycemic equipoise.
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Randomized, controlled trials are the cornerstone of modern, evidence-based medicine.1 Ran-domization in large-scale clinical outcome stud-
ies ensures that measured and unmeasured baseline 
confounders are balanced between treatment groups. 
Masking (or blinding) the treatment assignment fur-
ther minimizes the potential bias of differential post-
randomization management of enrolled participants. 
Many placebo-controlled cardiovascular (CV) outcome 
trials of glucose-lowering agents have been designed 
to minimize potential confounding by glycemic differ-
ences between treatment groups by applying treat-
to-guideline glycemic targets to all participants. This 
protocol requirement has in turn led to greater use of 
drop-in, open-label glucose-lowering agents after ran-
domization in the placebo group. Historically, this has 
not been a major concern, as available glucose-lower-
ing agents had not been proven to reduce or increase 
CV risk (eg, thiazolidinediones).2 Previous concerns that 
sulfonylureas might also increase CV risk have largely 
been ameliorated by the CAROLINA trial (Cardiovascu-
lar Outcome Study of Linagliptin Versus Glimepiride in 
Patients with Type 2 Diabetes).3 However, significant CV 
event reductions have been demonstrated for several 
newer medications in recent large-scale outcome trials. 
Liraglutide, semaglutide, albiglutide, and dulaglutide 
(glucagon-like peptide-1 receptor agonists [GLP-1 RAs]) 
showed 13%, 26%, 22%, and 12% relative risk re-
ductions (RRR), respectively, for a 3-point major adverse 
CV events (MACE) composite of CV death, nonfatal 
myocardial infarction, or nonfatal stroke in popula-
tions varying in their degree of CV risk.4–8 Liraglutide 
 
and oral semaglutide also showed 15% and 49% re-
ductions in all-cause mortality (ACM).4,5 Empagliflozin 
and canagliflozin (sodium-glucose cotransporter-2 in-
hibitors [SGLT-2is]) both showed a significant 14% RRR 
for MACE and reductions in ACM (32%, P<0.001 for 
empagliflozin and 13% [NS] for canagliflozin) in pop-
ulations either with or at risk of CVD.9,10 With these 
cardioprotective glucose-lowering agents being used 
increasingly in routine clinical practice, there is a great-
er likelihood that their open-label drop-in in placebo 
groups could impact clinical trial CV event rates and 
potentially bias study outcomes.
EXSCEL (Exenatide Study of Cardiovascular Event 
Lowering) was a multinational, placebo-controlled, 
pragmatic randomized, controlled CV outcome trial 
designed to assess the impact of once-weekly exena-
tide 2 mg versus placebo, when added to usual care in 
patients with type 2 diabetes mellitus (T2D) at a wide 
range of CV risk. The primary MACE result for exena-
tide demonstrated noninferiority, but not superiority, 
when compared with placebo (hazard ratio [HR], 0.91; 
95% CI, 0.83–1.00; P=0.061), and a reduced risk for 
ACM (HR, 0.86; 95% CI, 0.77–0.97; P=0.016) that was 
nominally significant because of the prespecified hier-
archical testing paradigm.11 Initiated in 2010, EXSCEL 
was designed to target comparable glucose control in 
both treatment arms.12 During the trial, management 
of T2D was performed by participants’ usual care pro-
viders, in accordance with local and national treatment 
guidelines, with the choice and adjustment of concomi-
tant glucose-lowering medications also at the discre-
tion of the usual care provider. All glucose-lowering 
medications were permitted, with the exception of 
open-label GLP-1 RAs. As a consequence of EXSCEL’s 
glycemic equipoise policy, there was greater drop-in 
use of open-label glucose-lowering medications in the 
placebo group. In these exploratory analyses, we have 
used several statistical and modeling methods to evalu-
ate whether their unbalanced use during the trial might 
have affected the primary outcome (MACE) or ACM 
time-to-event analyses.
METHODS
Because of the sensitive nature of the data collected for this 
study, requests to access the dataset from qualified research-
ers trained in human subject confidentiality protocols may be 
submitted at dcri.org/data-sharing.
Study Design
The design, protocol, and primary results of EXSCEL 
(NCT01144338) have been published previously.11–13 The 
study was designed and run independently by the Duke 
Clinical Research Institute and the University of Oxford 
Diabetes Trials Unit in an academic collaboration with the 
sponsor, Amylin Pharmaceuticals, a wholly owned subsid-
iary of AstraZeneca. The protocol was approved by the 
Clinical Perspective
What Is New?
• The design, conduct, and interpretation of pla-
cebo-controlled cardiovascular outcome trials in
type 2 diabetes mellitus is becoming more com-
plex because of the increasing use of proven car-
dioprotective glucose-lowering medications in this
population.
• Glycemic equipoise clinical trial designs inevitably
lead to a greater use of potentially cardioprotec-
tive medications in the placebo group, which could
mask the true cardiovascular benefits of an inter-
vention being studied.
What Are the Clinical Implications?
• The authors explore methodologies that can be
used to estimate the likely impact of drop-in car-
dioprotective glucose-lowering medications on car-
diovascular outcomes and to inform the design of
future cardiovascular outcome trials.
ethics committees associated with all participating trial 
sites, and all participants provided written informed con-
sent for trial participation.
Briefly, 14 752 participants from 35 countries were 
enrolled between June 2010 and September 2015. Eligible 
participants were adults (>18 years old) with T2D with HbA1c, 
6.5 to 10.0% (48–96 mmol/L) and any degree of previous CV 
risk, although the trial targeted 70% with a previous coro-
nary, cerebrovascular, or peripheral arterial event. Enrolled 
patients could be taking up to 3 oral glucose-lowering agents 
either alone or in combination with insulin. Key exclusion cri-
teria were a history of 2 or more episodes of severe hypogly-
cemia (defined as hypoglycemia for which a patient received 
third-party assistance) during the preceding 12 months, end-
stage kidney disease or an estimated glomerular filtration rate 
(eGFR) at entry <30 mL·min-1·1.73 m2, a personal or family 
history of medullary thyroid carcinoma or multiple endocrine 
neoplasia type 2, a baseline calcitonin level >40 ng/L, or pre-
vious treatment with a GLP-1 RA. Study participants were 
randomized in a double-blind fashion to either once-weekly 
exenatide 2 mg or matching placebo.
Open-Label Drop-In Glucose-Lowering 
Medications
During follow-up, treatment for T2D and its comorbidities 
was provided by usual care providers based on local guide-
lines, with an intent to achieve comparable glycemic control 
in the 2 treatment groups. The protocol instructions were: 
“Concomitant medications will be used at the discretion of 
the usual care physician (or investigator if also the usual care 
physician), who will be informed of the participant’s enrol-
ment in the trial, the use of blinded trial medication, and that 
use of GLP-1 receptor agonists is contraindicated during the 
trial period…Usual care physicians will be encouraged to fol-
low guidelines for care based on local and institutional prac-
tice patterns and any relevant published practice guidelines.” 
The addition of any glucose-lowering agent was permitted, 
with the exception of GLP-1 RAs, which, if started by the usual 
care provider, prompted discontinuation of study medication. 
Concomitant medication usage was recorded at all visits by 
drug class: metformin, sulfonylurea, thiazolidinedione, insulin 
(including short- and long-acting preparations), pramlintide, 
nonsulfonylurea secretagogue, α-glucosidase inhibitor, GLP-1 
RA (other than the study drug), and dipeptidyl peptidase-4 
inhibitor (DPP-4i). Data collection for SGLT-2i use, at baseline 
and/or during follow-up, commenced in May 2013, before 
extensive SGLT-2i use in routine clinical practice.14 For the pur-
poses of these analyses, SGLT-2i use was assumed not to have 
occurred before this date.
Statistical Analyses
Analyses were limited to glucose-lowering medication classes 
where open-label drop-in occurred in >5% of participants, 
and for the GLP-1 RAs that were used by fewer participants 
but were of special interest given previous studies demon-
strating their cardioprotective attributes. Drop-in medications 
were assumed to continue for the duration of the follow-
up period once initiated, as stopping dates were not col-
lected. Baseline characteristics for participants commencing 
open-label drop-in glucose-lowering medications were sum-
marized by medication class using mean±1 SD or median 
(25th, 75th percentile) for continuous variables, and by 
number (percentage) for categorical variables. Three differ-
ent methodologies were used to explore in the intention-to-
treat population the potential impact of within-trial drop-in 
medications on CV outcomes: (1) right censoring analyses; 
(2) inverse probability weighting analyses; and (3) applying 
evidence-based event rate adjustments. The latter methodol-
ogy was also used to simulate the potential impact of greater 
drop-in rates than observed in EXSCEL, which may well occur 
in future CV outcome trials in T2D.
Right Censoring Analyses
To exclude any impact of starting a concomitant diabetes mel-
litus medication postbaseline on estimation of the random-
ized treatment effect, time to event outcomes were analyzed 
using Cox proportional hazards regression models where 
patients who started drop-in medications were censored at 
the time of the visit where this occurred. Drop-in medication 
drug classes were analyzed separately, as well as drop-in of 
any diabetes mellitus medication. Patients taking the drug 
class at baseline were not censored for drop-in.
Inverse Probability Weighting Analyses
Inverse probability weighting methods were used to adjust 
for the potential impact of drop-in medications.15 Data from 
participants who initiated a drop-in medication were right 
censored at the time of drop-in (as mentioned previously), 
while event rates from those who did not initiate a drop-in 
medication were weighted by the inverse probability of start-
ing a drop-in medication, as calculated by a proportional 
hazards regression model. For example, if a 55-year-old male 
patient had one-third the probability of not starting a drop-in 
medication, his data would be weighted by a factor of 3 in 
the analysis, to account for himself and 2 similar patients who 
did start drop-in medication (and whose data were censored).
To conduct the analysis, a participant day–level dataset 
was created for each time interval from baseline until medi-
cation drop-in, an event of interest occurred, or study end. 
Probabilities of drop-in were calculated using proportional 
hazards regression models, separately for exenatide and pla-
cebo groups. Models included covariates of baseline age, sex, 
race, ethnicity, region, smoking, diabetes mellitus duration, 
New York Heart Association heart failure class, previous CV 
disease, myocardial infarction, percutaneous coronary inter-
vention, coronary artery bypass graft, cerebrovascular disease, 
chronic liver disease, chronic respiratory disease, hyperlip-
idemia, hypertension, atrial fibrillation, unstable angina, 
heart rate, body mass index, HbA1c, eGFR, and blood pres-
sure. HbA1c and eGFR measures taken during the study were 
included as time-varying covariates, as was hospitalization for 
heart failure. The inverse probabilities from this model were 
used to weight contributions from patients who did not initi-
ate a drop-in medication in the CV outcomes models, where 
randomized treatment was the only independent variable. 
Weights were truncated at the 99th percentile to minimize 
the impact of a few extreme values.
Evidence-Based Event Rate Adjustment Analyses 
Rates for events observed after drop-in medication during 
the trial were adjusted using estimates by diabetes mellitus 
medication class of their likely impact on the outcomes of 
interest. To obtain effect size estimates, we performed a lit-
erature search to identify published meta-analyses of ran-
domized, placebo-controlled trials listing MACE or ACM as 
primary or secondary outcomes within each drug class (Table 
I in the Data Supplement). Events occurring before the use 
of an open-label drop-in glucose-lowering medication were 
counted as observed, whereas counts of post–drop-in events 
were divided by the estimated HR for the medication class 
concerned. Hazard rates in each treatment group were 
obtained by dividing a sum of events before drop-in and 
amended events after drop-in by the total patient-years of 
follow-up, and HRs were then calculated (Table II in the Data 
Supplement).
To simulate the potential impact of a much greater rate 
of open-label drop-in glucose-lowering medication than was 
observed in EXCSEL, these analyses were repeated assum-
ing that 25% or 50% of placebo group participants, but 
no exenatide group participants, commenced such med-
ication—a worst-case scenario maximizing the potential 
for bias. Among placebo patients who were not taking the 
medication at baseline, additional patients were chosen at 
random to become drop-ins and were assumed to drop-in 
immediately at baseline. New follow-up times were simu-
lated from an exponential distribution for patients who 
died under the assumption that they may not have died had 
they received drop-in medication. New time to event was 
simulated for the additional drop-ins. If the simulated time 
was after the study ended or after the patient was actually 
censored, patients were assigned to be nonevents; other-
wise, they were assigned to be events. Proportional hazards 
regression analysis was performed using simulated data from 
additional drop-ins, as described previously, and actual data 
from all other patients. Estimates from the regression analysis 
were saved, and the process was repeated 5000 times for 
each drop-in medication. SAS PROC MIANALYZE was used to 
combine the estimates from the 5000 repetitions. Results are 
presented as median number of events across simulations, 
HR (95% CI), and P value.
RESULTS
At baseline, concomitant medication use did not dif-
fer between groups (Figure  1A). During follow-up, 
open-label drop-in of glucose-lowering medication 
occurred overall in 33.4% of participants, and more 
frequently in the placebo than the exenatide group 
(38.1% placebo versus 28.8% exenatide). Drop-in 
therapies were metformin (6.1% versus 4.9%), sul-
fonylurea (8.7% versus 6.9%), insulin (13.8% versus 
9.4%), DPP-4i (10.6% versus 7.5%), GLP-1 RA (3.4% 
versus 2.4%), and SGLT-2i (10.3% versus 8.1%; Fig-
ure  1B). Baseline characteristics for participants ini-
tiating open-label drop-in glucose-lowering medica-
tions by drug class show little age difference between 
medication type (Table). Patients initiating sulfonyl-
urea had the shortest duration of diabetes mellitus, 
and those starting metformin or an SGLT-2i had the 
longest. Participants initiating a GLP-1 RA had the 
 
highest body mass index followed by patients initiat-
ing an SGLT-2i. Median post–drop-in drug exposure 
times ranged from 1.0 to 2.1 years.
Right Censoring Analyses
The EXSCEL primary outcome (MACE) HR was not al-
tered meaningfully by right censoring for any of the 
drop-in medications, although the small changes in 
event numbers did lead to nominally significant P val-
ues when censoring for sulfonylureas (P=0.025) or any 
drop-in glucose-lowering medication (P=0.017; Fig-
ure  2A). The ACM HR was not altered meaningfully 
by right censoring for any of the drop-in medications, 
with no meaningful change in their associated P values 
(Figure 2B).
Inverse Probability Treatment Weighting 
Analyses
Using inverse probability weighting to account for the 
addition of drop-in medications increased the MACE 
effect size for exenatide, decreasing the HR from 0.91 
(95% CI, 0.83–1.00) to 0.85 (95% CI, 0.76–0.96) with 
a decrease in the P value from 0.061 to 0.008. Similarly, 
the ACM effect size for exenatide was increased, de-
creasing the HR from 0.86 (0.77–0.97) to 0.81 (0.69–
0.96) and decreasing the P value from 0.016 to 0.012. 
The factors most strongly associated with medication 
drop-in were HbA1c values during follow-up, region, 
and diabetes mellitus duration (Tables III through VI in 
the Data Supplement).
Evidence-Based Event Rate Adjustment 
Analyses
Our literature search identified suitable meta-analyses 
to estimate the impact on MACE and ACM for insulin,16 
DPP-4i,17 GLP-1 RA,18 and SGLT-2i19 (Table I in the Data 
Supplement). For metformin and sulfonylurea, suitable 
meta-analyses were only identified for ACM.20,21 MACE 
estimates for metformin and sulfonylurea were provid-
ed by the United Kingdom Prospective Diabetes Study 
Group (Rury Holman, personal communication).
Applying these evidence-based impact estimates to 
the MACE and ACM event rates observed after open-
label glucose-lowering drop-in of medication had oc-
curred did not meaningfully alter the HRs or confidence 
intervals seen for these outcomes in EXSCEL (Figure 3).
Simulating the Impact of a Substantially 
Greater Rate of Drop-In Medication
Simulation analyses using evidence-based event rate 
adjustments and the proportion of placebo-treated pa-
tients initiating drop-in medications set to 25% or to 
50% showed that MACE HRs remain largely unchanged 
from the main trial for most medications, ranging from 
0.91 to 0.93 for sulfonylurea, insulin, and DPP-4i, re-
gardless of the proportion with drop-in.
HRs were higher (>0.93) for metformin at 50% 
drop-in and for both GLP-1 RA and SGLT-2i at both 
25% and 50% drop-in, suggesting that upwards of 
25% of placebo-treated patients in EXSCEL would have 
needed to commence an SGLT-2i or GLP-1 RA to have 
made a substantive change to the MACE trial results. 
HRs for ACM were most markedly altered by GLP-1 RA 
and SGLT-2i drop-in, with reductions in effect size seen 
for both 25% and 50% drop-in, with loss of statistical 
significance in all cases.
Figure 1. Glucose-lowering medication use by treatment group in EXSCEL (Exenatide Study of Cardiovascular Event Lowering).
Pictured is medication use at baseline (A) and during follow-up (B). Data presented are only for those drop-in medication classes used in >5% of EXSCEL partici-
pants and for the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class that was used by fewer participants but is of special interest given previous studies 
demonstrating their cardioprotective attributes. Percentages are for available data from the intention-to-treat population. Information regarding sodium-glucose 
cotransporter-2 inhibitor (SGLT-2i) use was added to the electronic case report form on May 9, 2013. DPP-4i indicates dipeptidyl peptidase-4 inhibitor.
DISCUSSION
The once-weekly exenatide effect sizes observed in EX-
SCEL for the MACE primary outcome and ACM were 
effectively unchanged when exploratory analyses were 
performed using right censoring to preclude any impact 
of open-label drop-in glucose-lowering medications. 
 
Similarly, no meaningful changes were observed after 
applying literature-derived effect sizes to post open-
label drop-in medication event rates. Once-weekly 
exenatide effect sizes, however, were increased when 
inverse probability weighting was applied, with the 
MACE HR decreasing from 0.91 to 0.85 and achieving 
statistical significance. The already nominally significant 













Exposure time, y 2.0 (0.9–3.2) 2.1 (1.0–3.5) 2.0 (0.9–3.3) 1.8 (0.8–3.0) 1.5 (0.6–3.0) 1.0 (0.4–1.6)
Age at randomization, y 62 (56–69) 60 (54–67) 61 (54–67) 62 (56–68) 60 (53–66) 60 (53–66)
Female sex 307 (38.0%) 472 (41.1%) 663 (38.7%) 469 (35.2%) 184 (41.6%) 437 (32.2%)
Race
 White 615 (76.1%) 870 (75.9%) 1360 (79.3%) 974 (73.0%) 379 (85.9%) 1161 (85.6%)
 Black 61 (7.5%) 82 (7.1%) 98 (5.7%) 69 (5.2%) 21 (4.8%) 43 (3.2%)
 Asian 70 (8.7%) 103 (9.0%) 108 (6.3%) 187 (14.0%) 17 (3.9%) 112 (8.3%)
 Hispanic 61 (7.5%) 86 (7.5%) 133 (7.8%) 96 (7.2%) 20 (4.5%) 37 (2.7%)
 Other 1 (0.1%) 6 (0.5%) 15 (0.9%) 8 (0.6%) 4 (0.9%) 4 (0.3%)
Duration of type 2 diabetes mellitus, y 12 (6–18) 9 (5–14) 10 (6–15) 11 (7–17) 11 (7–17) 12 (7–17)
History of cardiovascular disease
 Coronary artery disease 451 (55.8%) 571 (49.7%) 745 (43.5%) 731 (54.8%) 217 (49.1%) 687 (50.6%)
 Cerebrovascular disease 144 (17.8%) 183 (15.9%) 240 (14.0%) 213 (16.0%) 61 (13.8%) 168 (12.4%)
 Peripheral artery disease 168 (20.8%) 178 (15.5%) 242 (14.1%) 170 (12.7%) 44 (10.0%) 156 (11.5%)
Heart failure 156 (19.3%) 145 (12.6%) 207 (12.1%) 174 (13.0%) 40 (9.0%) 152 (11.2%)
Systolic blood pressure, mm Hg 135 (124–148) 133 (124–145) 134 (123–145) 134 (123–144) 134 (123–143) 133 (123–144)
Diastolic blood pressure, mm Hg 80 (70–85) 80 (72–86) 80 (72–85) 80 (71–85) 78 (70–85) 80 (71–85)
Heart rate, bpm 72 (65–78) 72 (65–80) 72 (66–80) 72 (66–80) 73 (68–80) 73 (67–80)
Body mass index, kg/m2 32.4 (28.4–37.0) 32.0 (28.0–36.9) 32.0 (28.3–36.8) 31.8 (28.4–36.6) 35.0 (31.4–39.8) 33.6 (29.8–38.2)
HbA1c, % 8.1 (7.4–9.0) 8.0 (7.3–8.8) 8.3 (7.6–9.0) 8.2 (7.5–9.0) 8.1 (7.4–8.9) 8.1 (7.5–9.0)
LDL, mg/dL 88 (67–121) 87 (68–114) 86 (66–114) 86 (66–111) 82 (66–106) 81 (63–106)
eGFR, mL·min-1·1.73m2 73 (58–90) 80 (63–95) 78 (62–93) 77 (61–94) 79 (63–97) 83 (69–97)
 ≥90 212 (26.3%) 373 (32.6%) 524 (30.7%) 421 (31.7%) 156 (35.4%) 507 (37.4%)
 60–89 374 (46.3%) 547 (47.9%) 829 (48.6%) 606 (45.6%) 205 (46.5%) 687 (50.6%)
 30–59 221 (27.4%) 223 (19.5%) 353 (20.7%) 301 (22.6%) 80 (18.1%) 163 (12.0%)
 <30 0 0 0 1 (0.1%) 0 0
Cardiovascular medications
 Aspirin 521 (64.5%) 712 (62.0%) 1010 (58.9%) 848 (63.6%) 300 (67.9%) 865 (63.6%)
 Thienopyridines 160 (19.8%) 185 (16.1%) 231 (13.5%) 218 (16.3%) 57 (12.9%) 197 (14.5%)
 Any antiplatelets 598 (74.1%) 804 (70.2%) 1156 (67.4%) 983 (73.7%) 333 (75.3%) 990 (72.9%)
 ACEI or ARB 603 (74.6%) 869 (75.7%) 1283 (74.9%) 1043 (78.2%) 336 (76.0%) 1092 (80.4%)
 Beta blockers 464 (57.4%) 592 (51.6%) 865 (50.5%) 738 (55.3%) 236 (53.4%) 746 (54.9%)
 Calcium channel blockers 250 (30.9%) 338 (29.4%) 472 (27.5%) 404 (30.3%) 123 (27.8%) 428 (31.5%)
 Any antihypertensive 721 (89.2%) 1006 (87.6%) 1507 (87.9%) 1209 (90.6%) 393 (88.9%) 1242 (91.4%)
 Statin 582 (72.0%) 832 (72.5%) 1219 (71.1%) 1003 (75.2%) 336 (76.0%) 1063 (78.2%)
 Any lipid lowering medication 610 (75.5%) 864 (75.3%) 1302 (76.0%) 1045 (78.3%) 355 (80.3%) 1110 (81.7%)
Data are shown as n (%) for categorical variables and median (interquartile range) for continuous variables. 
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bpm, beats per minute; DPP-4i, dipeptidyl peptidase-4 inhibitor; 
eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; and SGLT-2i, 
sodium-glucose cotransporter-2 inhibitor.
ACM HR decreased from 0.86 to 0.81. P values for the 
MACE HR were also reduced after right censoring for 
sulfonylurea or the use of any drop-in medication. The 
unbalanced use of open-label drop-in glucose-lowering 
medications during EXCSEL was an inevitable conse-
quence of the protocol requirement to aim for glycemic 
equipoise between treatment groups. These analyses 
suggest that the CV effects of some agents might have 
had a discernible impact on the MACE and ACM find-
ings in EXSCEL.
Differential use of background diabetes mellitus 
medication, influenced by age, duration and control 
of diabetes mellitus, renal function, and other demo-
graphic and clinical factors, is a common characteristic 
of clinical trials. One of the key values of randomiza-
tion in large-scale trials is that these baseline charac-
teristics will be distributed evenly between treatment 
groups, thereby avoiding bias for measured outcomes. 
However, unequal drop-in of new medications during 
a trial is a nonrandomized event that requires careful 
consideration. The reasons for drop-in are difficult to 
discern and are likely multifactorial, ranging from the 
clinical need to intensify treatment in a progressive dis-
ease to issues of cost, concomitant illness, tolerability, 
or patient-led and physician-led preferences. Unequal 
drop-in of cardioprotective medications during fol-
low-up has the potential to reduce the number of CV 
events overall, and to a greater extent in the group(s) 
using them most frequently. Disproportionate reduc-
tion of events could reduce the effect size attributable 
to study medication in a clinical trial or, in a worst-case 
scenario, nullify a real difference. For the relatively few 
EXSCEL participants experiencing drop-in of glucose-
lowering medications known to be cardioprotective, 
the likely effects would appear to be too small to have 
impacted on the trial findings, but for future CV out-
come trials, significant background use of both medi-
cation classes is likely.
The 3 statistical and modelling approaches used here 
each provide different approaches to estimating the po-
tential impact of unequal between-group use of poten-
tially cardioprotective medications during the follow-up 
period of a randomized, controlled trial. The censor-
ing analysis, arguably the most conservative approach, 
simply discards data from patients after the time of 
drop-in. While this undeniably removes any influence 
attributable to the drop-in medication itself, it also re-
duces the number of participants contributing events, 
Figure 2. Right censored analyses.
Shown are analyses for (A) major adverse cardiovascular event and (B) all-cause mortality. “# Uncensored” indicates the number who were not censored because 
they had drop-in of the given medication before the event or end of follow-up for event. The number uncensored includes patients who were censored before 
event or end of follow-up because they had shorter follow-up for drop-in than for event. DPP-4i indicates dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; and SGLT-2i, sodium-glucose cotransporter-2 inhibitor.
reducing the power to detect treatment-related differ-
ences. Right-censoring may also introduce bias because 
it is a nonrandom event that may result from multiple 
or multifactorial causes that likely differ in the exenatide 
group (eg, inability to tolerate exenatide or inadequate 
 
durability of glycemic impact of exenatide) compared 
with the placebo group (routine intensification of ther-
apy). It is reassuring, however, that no meaningful im-
pact is seen on the EXSCEL findings when using this 
robust methodology.
Figure 3. Evidence-based effect size adjustment analyses.
Shown are analyses for (A) major adverse cardiovascular event and (B) all-cause mortality. These outcomes were adjusted for risk reductions attributable to drop-in 
medication, as derived from published placebo-controlled studies. The first row for each medication shows the number of patients in each treatment group who 
began the medication during the trial and the number experiencing events, thereby estimating the within-trial impact of drop-in medications. The second and 
third rows for each medication class show the simulated effect if drop-ins had been more pervasive (25% or 50% of placebo-treated patients) than was seen in 
EXSCEL (Exenatide Study of Cardiovascular Event Lowering). For both metformin and insulin, drop-in within EXSCEL was seen in 25% of participants and these 
results have not been re-estimated in the sensitivity analysis. DPP-4 indicates dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist; HR, 
hazard ratio; and SGLT-2, sodium-glucose cotransporter-2 inhibitor.
Inverse probability weighting analysis gives a comple-
mentary view in which event data for patients are not 
calculated according to medication class, but according 
to the overall likelihood of starting any new medication. 
Data from those starting new medications are still lost 
after censoring, but observations remaining in the anal-
ysis are not treated equally. Participants with a higher 
probability of starting a new medication—in this case, 
patients with longer duration of diabetes mellitus and 
higher HbA1c—contribute less toward the assessment 
of outcomes than those less likely to experience drop-
in. Inverse probability weighting is used to reduce bias 
by indication introduced in postrandomization medica-
tion selection, but it should be noted that some fac-
tors predicting medication drop-in may have more to 
do with regional differences in health care systems and 
availability of medications than with individual patient 
characteristics.
The application of externally derived effect sizes for 
each medication class takes an alternative approach 
to quantifying the impact of concomitant medication 
drop-in. Here, the number of within-trial events accrued 
for EXSCEL patients before the commencement of 
medication drop-in was added to the number of events 
accrued after drop-in, with the latter adjusted both by 
an HR derived from the literature to approximate the 
impact of the medication and by a maximum estimate 
of potential exposure time to the drop-in medication. 
These amended event numbers were then used to cal-
culate revised HRs and confidence intervals to account 
for the likely evidence-based changes in risk attribut-
able to drop-in medication for the duration that they 
were taken. While this approach was relatively straight-
forward for newer diabetes mellitus medications which 
all have had multiple well-conducted CV outcome trials 
informing robust meta-analyses, the exercise was more 
difficult for older medications for which little CV out-
comes data exist to derive a credible attributable “class 
effect.” The meta-analysis driven adjustment factors 
available likely overestimate the population impact on 
MACE for medication classes studied, a well-described 
phenomenon in clinical research,22 and particularly for 
trials using composite outcomes.23 However, estimates 
for ACM tend to be more robust at the population level 
because there are fewer confounders related to the use 
of surrogate outcomes, event definitions, or event ac-
quisition. Finally, this approach attributed the value of 
a medication class effect, potentially ignoring situations 
in which one drug in a class has a markedly different 
degree of benefit. The analyses performed here again 
provide reassurance that, for EXSCEL, the within-trial 
impact of drop-in medications, particularly for GLP-1 
RAs and SGLT-2is, was small.
Simulating substantially greater imbalances of open-
label drop-in glucose-lowering medications that are 
cardioprotective shows that these agents could have 
the ability to blunt signal detection for some endpoints. 
Such impacts need to be carefully considered when 
designing and conducting future CV outcome trials 
in T2D, possibly informed by the methodologies used 
in this study. Given the proven CV benefit for some 
glucose-lowering agents, their use will become wide-
spread, and it would be unethical to prohibit their use 
during clinical trials, particularly those enrolling patients 
at high CV risk.
There are other limitations to consider in interpret-
ing these data. EXSCEL was neither designed nor pow-
ered to look for treatment differences according to 
concomitant medication use. Power was further limited 
by the small sample sizes within each medication sub-
group. Likewise, medication exposure times, although 
comparable between medication classes (ranging from 
1.0–2.1 years), are short when compared with potential 
lifetime exposures more typical of routine clinical prac-
tice for patients with T2D, making predictions for lon-
ger term outcomes difficult. It is possible that exposure 
times for new medications have been overestimated if 
the assumption that newly initiated medications con-
tinued throughout follow-up is untrue, a limitation that 
would primarily affect the evidence-based modeling. In 
clinical practice, switching and stopping new medica-
tions is common as a result of adverse events, inad-
equate response, nonadherence, and other changes 
in circumstances. We are also unable to comment on 
the potential impact of combination therapies because 
these analyses have considered each medication class 
independently.
The advent of drugs providing simultaneous glu-
cose lowering and cardioprotection is a major thera-
peutic advance in diabetes mellitus treatment. Future 
CV outcome trials will require some mechanism to 
account for the impact of nonrandomized drop-in of 
these medications during trial follow-up. Although 
we have demonstrated that observed MACE and 
ACM effect sizes for EXSCEL were robust to multiple 
methods of adjusting for the greater drop-in of diabe-
tes mellitus medications in the placebo arm, drop-in 
for some medications induced small changes in event 
numbers that altered the assessment of statistical 
significance for MACE. In EXSCEL, the proportion of 
patients experiencing drop-in of potentially cardio-
protective medications (eg, SGLT-2is and GLP-1 RAs) 
was small; however, on a larger scale as is simulated 
here, the influence of these medications could blunt 
signal detection and alter future study conclusions. 
Because we believe it to be unethical to withhold 
proven CV risk-lowering treatments in trials enrolling 
participants with T2D with clinical atherosclerotic CV 
disease or heart failure, prohibiting the use of these 
medications in future CV outcome trials is not the an-
swer. Careful consideration in future trials should fac-
tor in the unbalanced drop-in of these agents for the 
placebo group, their growing use in routine clinical 
practice, a likely steady increase in numbers of par-
ticipants experiencing drop-in during trial follow-up, 
and the potential cardioprotective impact attributable 
to each medication class.
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